These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

296 related items for PubMed ID: 17275249

  • 1. Reduction of plasma taurine level in children affected by osteogenesis imperfecta during bisphosphonate therapy.
    D'Eufemia P, Finocchiaro R, Zambrano A, Tetti M, Ferrucci V, Celli M.
    Biomed Pharmacother; 2007 May; 61(4):235-40. PubMed ID: 17275249
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study.
    Gatti D, Antoniazzi F, Prizzi R, Braga V, Rossini M, Tatò L, Viapiana O, Adami S.
    J Bone Miner Res; 2005 May; 20(5):758-63. PubMed ID: 15824848
    [Abstract] [Full Text] [Related]

  • 4. Intravenous neridronate in adults with osteogenesis imperfecta.
    Adami S, Gatti D, Colapietro F, Fracassi E, Braga V, Rossini M, Tatò L.
    J Bone Miner Res; 2003 Jan; 18(1):126-30. PubMed ID: 12510813
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The effect of cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta type V.
    Zeitlin L, Rauch F, Travers R, Munns C, Glorieux FH.
    Bone; 2006 Jan; 38(1):13-20. PubMed ID: 16162424
    [Abstract] [Full Text] [Related]

  • 10. Biochemical bone markers in the assessment and pamidronate treatment of children and adolescents with osteogenesis imperfecta.
    Aström E, Magnusson P, Eksborg S, Söderhäll S.
    Acta Paediatr; 2010 Dec; 99(12):1834-40. PubMed ID: 20726960
    [Abstract] [Full Text] [Related]

  • 11. No osteonecrosis in jaws of young patients with osteogenesis imperfecta treated with bisphosphonates.
    Malmgren B, Aström E, Söderhäll S.
    J Oral Pathol Med; 2008 Apr; 37(4):196-200. PubMed ID: 18321345
    [Abstract] [Full Text] [Related]

  • 12. Osteogenesis imperfecta: anthropometric, skeletal and mineral metabolic effects of long-term intravenous pamidronate therapy.
    Vallo A, Rodriguez-Leyva F, Rodríguez Soriano J.
    Acta Paediatr; 2006 Mar; 95(3):332-9. PubMed ID: 16497645
    [Abstract] [Full Text] [Related]

  • 13. Pamidronate does not adversely affect bone intrinsic material properties in children with osteogenesis imperfecta.
    Weber M, Roschger P, Fratzl-Zelman N, Schöberl T, Rauch F, Glorieux FH, Fratzl P, Klaushofer K.
    Bone; 2006 Sep; 39(3):616-22. PubMed ID: 16644299
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Large osteoclasts in pediatric osteogenesis imperfecta patients receiving intravenous pamidronate.
    Cheung MS, Glorieux FH, Rauch F.
    J Bone Miner Res; 2009 Apr; 24(4):669-74. PubMed ID: 19063679
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Osteogenesis imperfecta, current and future medical treatment.
    Rauch F, Glorieux FH.
    Am J Med Genet C Semin Med Genet; 2005 Nov 15; 139C(1):31-7. PubMed ID: 16278881
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.